News

Commission funds Mutabilis project
Enlarge image

FundingFranceEU

Commission funds Mutabilis project

19.09.2012 - Mutabilis has received €4m funding from the European Union under its FP7 programme.

The project, submitted by the French specialist for infectious diseases, is called "HIVINNOV – generation of a new class of antiretrovirals targeting HIV-cellular cofactors interactions". Mutabilis, which is the coordinator of the €10.8m project, formed the consortium in July 2011 comprising eleven research institutions from across Europe. "The Commission was apparently very impressed with the major advances we have made with the compounds we are developing, as well as the quality of the consortium and the research projects proposed," said the scientific director of Mutabilis, Dr. Richard Benarous.

Mutabilis was founded in 2001 to develop new antibiotic treatments.  The French company raised €11.8m in two financing rounds in 2002 and 2004. Mutabilis runs different collaborations, amongst others with German drug developer 4SC. In 2009 FAB Pharmaceuticals SAS acquired Mutabilis lead compound Fab-001, which is a marrow- spectrum antibiotic targeting the fatty acid biosynthesis in S. aureus. Since 2010, the company has been an affiliate of Pharma Omnium International.

The European Union's seventh framework program (FP7), which has been allotted a total budget of €50.5bn for the 2007-2013 period, brings together all the EU's research initiatives under one roof and plays an important role in achieving its growth, competitiveness and employment targets. A budget of €6.05 billion has been assigned to cooperation in human health.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-03/commission-funds-mutabilis-project.html

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC5.41 EUR4.04%
  • WILEX5.25 EUR3.35%
  • BIOFRONTERA2.34 EUR1.74%

FLOP

  • VITA 345.86 EUR-6.69%
  • FORMYCON26.31 EUR-6.04%
  • MORPHOSYS63.42 EUR-6.02%

TOP

  • 4SC5.41 EUR322.7%
  • WILEX5.25 EUR83.6%
  • PAION2.85 EUR21.3%

FLOP

  • BIOTEST72.00 EUR-25.9%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.16 EUR-17.6%

TOP

  • SANTHERA96.00 CHF2361.5%
  • CYTOS1.27 CHF647.1%
  • WILEX5.25 EUR517.6%

FLOP

  • MOLOGEN4.85 EUR-55.5%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.34 EUR-26.6%

No liability assumed, Date: 05.05.2015